The class I innovative drug NIP046 developed by CR Pharmaceutical was approved for clinical trial targeting rheumatoid arthritis indications.
The class I innovative drug NIP292 obtained the Orphan Drug Designation (ODD) issued by the Food and Drug Administration (FDA) for the treatment of idiopathic pulmonary fibrosis (IPF).
CR Double-Crane acquired 38.75% of the stake of Dongying Tiandong Pharmaceutical Co., Ltd.
CR Pharmaceutical completed the reorganization of CR Jiangzhong. By then, Jiangxi Jiangzhong Pharmaceutical (Group) Co., Ltd. (Jiangzhong Group) was renamed China Resources Jiangzhong Pharmaceutical Group Co., Ltd. (CR Jiangzhong) and was listed as a first-level profit center in CR Pharmaceutical’s management sequence.
CR Sanjiu, CR Double-Crane, and Dong-E-E-Jiao were officially included in the FTSE Russell Global Index.
The class I innovative drug NIP292 for the treatment of idiopathic pulmonary fibrosis (IPF) obtained the approval of FDA for Phase I clinical trial.
CR Double-Crane held a meeting for celebrating the company’s 80th anniversary of its foundation in Beijing.
CR signed a strategic cooperation agreement with the People’s Government of Jiangxi for the reorganization of Jiangzhong Group. CR Pharmaceutical acquired or subscribed over 51% stake of Jiangzhong Group equity through cash or assets.
CR Pharmaceutical was selected as a constituent stock of the Hang Seng Corporate Sustainability Benchmark Index.
CR Sanjiu and Dong-E-E-Jiao were listed in the MSCI Emerging Market Index.
CR Double-Crane acquired Hunan Xiangzhong Pharmaceutical Co., Ltd.
CR Pharmaceutical was listed as a constituent stock in the Hang Seng Composite LargeCap Index, the Hang Seng Mainland Healthcare Index, the Hang Seng Healthcare Index, the Hang Seng China-Affiliated Corporations Index, the Hang Seng China (Hong Kong-listed) 100 Index, the FTSE Global Equity Index Series (Large Cap), the FTSE All-World Index Series, the FTSE Global All Cap Index, and the MSCI China Index.
CR Sanjiu acquired 65% of the equity of Jilin Jinfukang Pharmaceutical Co., Ltd. and 65% of the equity of Shandong Shenghai Health Products Co., Ltd. CR Double-Crane acquired 100% of the equity of Hainan Zhong Hua Lian He Pharmaceutical. Co., Ltd.
We completed the acquisition of 100% interest in CR Pharmaceutical Retail Group which wholly owned CR Care, a company principally engaged in pharmacy business in China and Hong Kong.
CR Pharmaceutical Holdings was awarded the “Top 10 PRC Pharmaceutical Group of 2015 (中国医药行业企业集团十强)” at the ChemPharm Annual Summit 2015(2015中国化学制药行业年度峰会).
Our Company ranked No.4 among the “Top 100 Enterprises in the PRC Pharmaceutical Industry of 2013 (2013年度中国医药工业百强企业”.
CR Pharmaceutical Holdings was awarded the “Top 10 PRC Pharmaceutical Group of 2014 (中国医药行业企业集团十强)” at the ChemPharm Annual Summit 2014 (2014中国化学制药行业年度峰会).
The Beijing Pharmaceutical Group Industry-University-Research Alliance (北京医药集团产学研联盟) led by our Company under the Eleventh-Five Year Plan was successfully completed and accepted.
BEID Fund became a shareholder of our Company.
The total assets and revenue of our Group for the year respectively exceeded HK$100 billion for the first time.
CR Pharmaceutical Commercial became a wholly-owned subsidiary of our Company.
We acquired the remaining 52.72% interest in CR Zizhu to further develop our product portfolio and enhance our market penetration.
Pharmaceutical R&D Center became our wholly-owned subsidiary.
We established the Health Institute of China Resources University (华润大学健康学院) in June 2012.
We acquired the remaining 50% interest in Beijing Pharmaceutical, and thereafter Beijing Pharmaceutical became a wholly-owned subsidiary of our company.
Beijing Pharmaceutical investment became a Share holder of our Company.
We successfully completed 11 mergers and acquisitions in Beijing, Jiangsu, Henan and other provinces, which further developed our core businesses and enhanced our presence in the pharmaceutical market in China.
Our company entered into a strategic cooperation agreement with the China Academy of Medical Sciences (中国医学科学院) to strengthen the research and development capabilities of our Group.
We acquired 50% interest in Beijing Pharmaceutical from CRC.
CR Double-Crane became our non-wholly owned subsidiary following the completion of acquisition of 50% interest in Beijing Pharmaceutical.
We acquired 56.62% interest in CR Dong-E from CRC, thereby controlling 23.14% interest in Dong-E-E-Jiao, a company listed on the Shenzhen Stock Exchange and principally engaged in the manufacturing of E Jiao (donkey-hide gelatin) products.
We completed the acquisition of 66.98% interest in CR Sanjiu, a company listed on the Shenzhen Stock Exchange and principally engaged in the manufacturing and sale of OTC drugs and Chinese prescription medicine.
Our Company was incorporated in Hong Kong.
CRC was engaged in the restructuring of China Worldbest, and acquired 50% interest in Beijing Pharmaceutical.
CRC set up CR Done-E with Liaocheng SASAC (the State-Owned Assets Supervision and Administration Commission of the State Council).
Our controlling shareholder, China Resources Holdings, was incorporated in Hong Kong.
China Resources Company (华润公司) started to export medicines and medical devices to mainland China.
Liow & Company (联合行) was renamed as China Resources Company (华润公司)
Liow & Company (联合行), the predecessor of China Resources Holdings, our controlling shareholder, was founded.
